Novo Nordisk A/S (HAM:NOV) Institutional Ownership : 32.30% (As of Jun. 12, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Novo Nordisk A/S Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Novo Nordisk A/S's institutional ownership is 32.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Novo Nordisk A/S's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Novo Nordisk A/S's Float Percentage Of Total Shares Outstanding is 71.58%.

Novo Nordisk A/S Institutional Ownership Historical Data

The historical data trend for Novo Nordisk A/S's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Institutional Ownership Chart

Novo Nordisk A/S Historical Data

The historical data trend for Novo Nordisk A/S can be seen below:

	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	16.80	33.05	32.96	32.91	33.62	33.61	33.54	32.19	32.28	32.30

Novo Nordisk A/S Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Novo Nordisk A/S (HAM:NOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (HAM:NOV) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.